Thymic & Immune

Thymic and immune peptides are compounds derived from or mimicking thymic hormones, the signaling molecules produced by the thymus gland to orchestrate T-cell maturation and adaptive immune function. The thymic peptide family represents one of the oldest peptide therapeutic lineages, with thymosin-derived compounds in clinical investigation since the 1970s. As the thymus involutes with age, thymic peptide levels decline substantially; this category addresses the immunological consequences of thymic aging.

Thymosin Alpha-1 (TA-1) is a 28-amino-acid peptide that modulates multiple layers of immune function: it promotes T-helper 1 cell maturation, enhances NK cell cytotoxicity, stimulates dendritic cell antigen presentation, and suppresses pro-inflammatory cytokines (TNF-α, IL-6, IL-1β) through toll-like receptor signaling modulation. Thymulin is a zinc-dependent nonapeptide (Glu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn) secreted exclusively by thymic epithelial cells; it requires zinc for bioactivity and promotes T-cell differentiation and proliferation. Thyalin is a thymic peptide preparation with similar T-cell regulatory properties. Collectively, these peptides help restore immune competence in immunocompromised or immunosenescent states.

Thymosin Alpha-1 (brand name Zadaxin, SciClone Pharmaceuticals) is approved in over 35 countries for chronic hepatitis B, chronic hepatitis C, and as an immune adjuvant in sepsis and cancer treatment. It is not FDA-approved in the United States but is available through 503A compounding pharmacies under clinician prescription. Thymulin and Thyalin are available through compounding pharmacies and have no regulatory approval in Western markets.

TA-1 has the most internationally robust evidence base of any non-FDA-approved peptide in regular clinical use. Large Phase III trials from Asian clinical programs (particularly China) demonstrated efficacy in chronic HBV and HCV. Meta-analyses support its role as an immune adjuvant in sepsis, reducing secondary infection rates. Emerging evidence in long COVID, cancer immune support, and post-chemotherapy immune reconstitution is accumulating. Thymulin has moderate laboratory and small trial evidence; human longevity and immune-aging data is limited but mechanistically coherent.

Internal links go to compound monograph pages in the Peptide Association database. External links go to Peptide Desk Reference.

• Thymosin Alpha-1Awaiting FDA decision
• ThymulinNo lawful US pathway
• ThyalinExternal

• Chronic viral hepatitis (B and C), approved indication internationally
• Sepsis and critical illness immune support
• Oncology immune adjuvant and post-chemotherapy immune reconstitution
• Recurrent infections and immune deficiency states
• Long COVID immune dysregulation
• Age-related immunosenescence protocols

1. 01

   Thymosin Alpha-1 is one of the best-evidenced non-FDA-approved peptides available, the evidence base is real, even if Western approval is lacking

2. 02

   Thymulin requires zinc for biological activity; zinc status should be assessed before use

3. 03

   This category is commonly paired with Category 4 (bioregulators) in comprehensive immune-aging protocols

4. 04

   TA-1's safety profile across decades of international clinical use is well-characterized, adverse events are rare

5. 05

   Patients with autoimmune conditions should approach thymic immune peptides cautiously; immune upregulation may exacerbate some autoimmune presentations

• 02Regenerative / NO-ReceptorTissue repair and angiogenesis via nitric oxide and growth factor pathways
• 04Bio-RegulatorsUltra-short tissue-targeted peptides that modulate gene expression and aging
• 12Sleep & CircadianPeptides that regulate sleep architecture, melatonin, and circadian entrainment